on16.10.2025 Adara Molinero Returns to Survivientes All Stars with Quietly Turbulent Welcome Adara Molinero Returns to the Set of Survivientes All Stars and Faces a Quietly Turbulent Welcome Adara Molinero has come back to the set of… Discover More
on16.10.2025 Denisovans: High-Altitude Lifeways Revealed An international team of researchers from China, Denmark and several other nations has uncovered bones and a collection of tools tied to… Discover More
on16.10.2025 Underwater flame — Losharik and the secrets of the deep Underwater flame The fire on the AS-31 Losharik in July 2019 marked a rare tragedy for the Russian submarine fleet since the Nerpa incident in… Discover More
on16.10.2025 Rising postponement in a high-profile trial A notable delay in the case has taken center stage. Pedro Lozano Jiménez, often referred to in the media as the “Rambo of… Discover More
on16.10.2025 Iran’s presidential election: Pezeshkian vs. Jalili — the lesser evil and the stakes An influential yet previously little-known member of Iran’s reformist wing or a high-ranking ultraconservative official. On Friday, Iran… Discover More
on16.10.2025 Russian Aerial Bombs in Ukraine: Reports, Context, and Implications Russian Aerial Bombs in Ukraine: Reports and Context Recent reports from regional observers describe an airstrike by the Russian Aerospace… Discover More
on16.10.2025 Belgorod Region Reports Drone Attacks and Air Defense Interceptions The Belgorod region’s Grayvoronsky urban district witnessed a series of drone and air defense incidents involving Ukrainian forces, according… Discover More
on16.10.2025 Advances in Neuroprosthetics: AMI Controls for Bionic Legs Enhance Mobility Researchers at a prestigious American institution have conducted a sequence of pioneering trials focused on cybernetic prosthetics that… Discover More
on16.10.2025 Survey Insights: Renovation Plans, Attitudes, and Trends in Russia Survey Insights Show Strong Renovation Interest Across Russia with Healthy Skepticism About the Process A recent survey reveals that more than… Discover More
on16.10.2025 How Donanemab Fits Into Alzheimer’s Disease Care in North America Donanemab stands as the second therapy in the United States approved to slow the progression of Alzheimer’s disease, offering a distinct… Discover More